NCT02057380View on ClinicalTrials.gov

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2014

Primary Completion Date

October 14, 2016

Study Completion Date

December 21, 2016

Conditions

Advanced Solid Tumors

Interventions

DRUG

linsitinib

oral

DRUG

erlotinib

oral

DRUG

paclitaxel

Intravenous (IV) infusion

DRUG

Bortezomib

Subcutaneous or IV

DRUG

Dexamethasone

IV, Oral

Trial Locations (12)

10117

Site DE49002, Berlin

21287

Site US10002, Baltimore

33612

Site US10006, Tampa

40002

Site TH66003, Khon Kaen

48109

Site US10008, Ann Arbor

70852

Site CZ42001, Ostrava-Poruba

73104

Site US10001, Oklahoma City

97080

Site DE49001, Würzburg

308433

Site SG65002, Singapore

92093-0987

Site US10004, La Jolla

90610-000

Site BR55005, Porto Alegre

70-891

Site PL48001, Szczecin

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02057380 - A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | Biotech Hunter | Biotech Hunter